A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER".

Ogale, Sarika; Zerbini, Clarissa Emy Higuchi; Antoniou, Miranta; Freund, Romain

Ogale, Sarika; Zerbini, Clarissa Emy Higuchi; Antoniou, Miranta; Freund, Romain.

Afiliação

Ogale S; Genentech South Francisco, CA.
Zerbini CEH; F. Hoffmann-La Roche Basel, Switzerland.
Antoniou M; F. Hoffmann-La Roche Basel, Switzerland.
Freund R; F. Hoffmann-La Roche Basel, Switzerland.

J Manag Care Spec Pharm ; 26(12): 1616-1617, 2020 12.

Article em En | MEDLINE | ID: mdl-33251994

ABSTRACT

ABSTRACT

DISCLOSURES The writing of this letter was sponsored by Roche/Genentech. All authors are employees of, and hold stocks in, F. Hoffmann-La Roche Ltd/Genentech Inc.

Assuntos

Neoplasias Pulmonares; Inibidores de Proteínas Quinases; Benzamidas; Humanos; Indazóis; Pirazóis; Pirimidinas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google